ADMA Biologics Inc (ADMA) Posts Quarterly Earnings Results, Misses Expectations By $0.29 EPS

ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings data on Friday. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.29, Bloomberg Earnings reports. The firm had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $3.52 million.

ADMA Biologics (NASDAQ ADMA) traded up 1.03% during trading on Friday, hitting $2.94. 36,784 shares of the company traded hands. The stock’s market capitalization is $37.88 million. ADMA Biologics has a 52 week low of $2.76 and a 52 week high of $7.70. The company’s 50 day moving average is $3.47 and its 200-day moving average is $4.19.

TRADEMARK VIOLATION NOTICE: “ADMA Biologics Inc (ADMA) Posts Quarterly Earnings Results, Misses Expectations By $0.29 EPS” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at

Several research firms have recently weighed in on ADMA. ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Maxim Group set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Wednesday, June 7th.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Earnings History for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply